CSPC Pharmaceutical Group (1093.HK) Stock Price

CSPC Pharmaceutical Group Price

🇨🇳HKEX·CLOSED
6.10CNY
Market closed
Today +/-
Today %

CSPC Pharmaceutical Group (1093.HK) Stock | ISIN HK1093012172 | WKN 548183. The current CSPC Pharmaceutical Group stock price is 6.1 CNY (2026). Revenue is 31.23 B CNY. Net income is 6.01 B CNY. The P/E ratio is 11.91. Market capitalization is 71.61 B CNY. CSPC Pharmaceutical Group operates in the Health sector.

Over the last 19 years CSPC Pharmaceutical Group grew revenue by 12% annually, reaching 29.01 B CNY. Earnings per share have grown at 6.7% per year over the last 19 years. For CSPC Pharmaceutical Group, the net margin of 14.9% is down versus 20.7% a few years ago. At today's price the dividend yield works out to roughly 5.57%. The payout ratio is around 37% of earnings. The dividend has grown at 12.7% per year over the past 16 years.

CSPC Pharmaceutical Group stock price

Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of CSPC Pharmaceutical Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how CSPC Pharmaceutical Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing CSPC Pharmaceutical Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

CSPC Pharmaceutical Group Stock Price History
DateCSPC Pharmaceutical Group Price
Access this data via the Eulerpool API
Get Free API Key

CSPC Pharmaceutical Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2005
3.36 B CNY
230 M CNY
165 M CNY
Jan 1, 2006
3.63 B CNY
103 M CNY
16 M CNY
Jan 1, 2007
4.86 B CNY
669 M CNY
465 M CNY
Jan 1, 2008
6.1 B CNY
1.09 B CNY
839 M CNY
Jan 1, 2009
6.2 B CNY
1.04 B CNY
855 M CNY
Jan 1, 2010
6.77 B CNY
950 M CNY
655 M CNY
Jan 1, 2011
6.13 B CNY
312 M CNY
194 M CNY
Jan 1, 2012
3.37 B CNY
613 M CNY
1.76 B CNY
Jan 1, 2013
7.89 B CNY
948 M CNY
771 M CNY
Jan 1, 2014
9.84 B CNY
1.5 B CNY
1.14 B CNY
Jan 1, 2015
9.5 B CNY
1.81 B CNY
1.39 B CNY
Jan 1, 2016
11.08 B CNY
2.38 B CNY
1.88 B CNY
Jan 1, 2017
13.85 B CNY
3.14 B CNY
2.48 B CNY
Jan 1, 2018
17.72 B CNY
3.73 B CNY
3.08 B CNY
Jan 1, 2019
22.1 B CNY
4.65 B CNY
3.71 B CNY

CSPC Pharmaceutical Group Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 16, 2026, 6:14 AM
 
REVENUE (B CNY)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B CNY)
NET INCOME (B CNY)
NET INCOME GROWTH (%)
DIV. (CNY)
DIV. GROWTH (%)
SHARES (B)
DOCUMENTS
20242025e2026e2027e2028e2029e2030e2031e
29.0128.5131.2332.0633.1235.8938.4841.05
-7.76-1.739.552.663.38.377.226.66
69.9771.26563.3161.2956.5552.7549.45
20.320.320.320.320.320.320.320.3
4.335.066.015.895.025.635.95-
-26.3116.8218.89-2.1-14.65125.69–
0.340.240.190.19----
36-29.41-20.83–––––
11.7411.7411.7411.7411.7411.7411.7411.74
––––––––
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales CSPC Pharmaceutical Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue CSPC Pharmaceutical Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare CSPC Pharmaceutical Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares CSPC Pharmaceutical Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against CSPC Pharmaceutical Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

CSPC Pharmaceutical Group stock margins

The CSPC Pharmaceutical Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CSPC Pharmaceutical Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CSPC Pharmaceutical Group.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2005
21.72 %
6.84 %
4.91 %
Jan 1, 2006
17.32 %
2.84 %
0.44 %
Jan 1, 2007
30.82 %
13.77 %
9.57 %
Jan 1, 2008
33.4 %
17.83 %
13.76 %
Jan 1, 2009
32.25 %
16.82 %
13.8 %
Jan 1, 2010
29.24 %
14.02 %
9.67 %
Jan 1, 2011
20.08 %
5.09 %
3.17 %
Jan 1, 2012
43.53 %
18.18 %
52.16 %
Jan 1, 2013
31.49 %
12.02 %
9.78 %
Jan 1, 2014
38.22 %
15.25 %
11.58 %
Jan 1, 2015
45.82 %
19 %
14.62 %
Jan 1, 2016
51 %
21.48 %
16.98 %
Jan 1, 2017
60.44 %
22.65 %
17.92 %
Jan 1, 2018
66.25 %
21.03 %
17.39 %
Jan 1, 2019
71.98 %
21.03 %
16.8 %

CSPC Pharmaceutical Group Stock Revenue, EBIT, Earnings per Share

The CSPC Pharmaceutical Group earnings per share therefore indicates how much revenue CSPC Pharmaceutical Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2005
2.19 CNY
0.15 CNY
0.11 CNY
Jan 1, 2006
2.36 CNY
0.07 CNY
0.01 CNY
Jan 1, 2007
3.16 CNY
0.43 CNY
0.3 CNY
Jan 1, 2008
3.96 CNY
0.71 CNY
0.55 CNY
Jan 1, 2009
4.04 CNY
0.68 CNY
0.56 CNY
Jan 1, 2010
4.41 CNY
0.62 CNY
0.43 CNY
Jan 1, 2011
4 CNY
0.2 CNY
0.13 CNY
Jan 1, 2012
0.74 CNY
0.13 CNY
0.38 CNY
Jan 1, 2013
1.34 CNY
0.16 CNY
0.13 CNY
Jan 1, 2014
1.65 CNY
0.25 CNY
0.19 CNY
Jan 1, 2015
0.83 CNY
0.16 CNY
0.12 CNY
Jan 1, 2016
0.96 CNY
0.21 CNY
0.16 CNY
Jan 1, 2017
1.18 CNY
0.27 CNY
0.21 CNY
Jan 1, 2018
1.48 CNY
0.31 CNY
0.26 CNY
Jan 1, 2019
1.85 CNY
0.39 CNY
0.31 CNY

CSPC Pharmaceutical Group business model & stock analysis

CSPC Pharmaceutical Group Ltd. is a leading pharmaceutical company in China. It was founded in 1997 and specializes in the manufacturing of pharmaceutical raw materials, intermediates, and finished drugs. The company's product range covers various therapy areas and provides a variety of medications for patients worldwide. The company's business model is based on research, development, and production of pharmaceutical products for the mass market. In 2019, CSPC Pharmaceutical achieved a revenue of 9.9 billion USD. The company's products are represented in 24 countries worldwide and aim to improve people's lives through innovations in the healthcare sector. CSPC Pharmaceutical has various divisions, including its sister company CSPC Zhongqi Pharmaceutical Technology Co. Ltd., which specializes in innovative technologies for drug manufacturing. Other divisions include CSPC Weisheng Pharmaceutical Co. Ltd. for marketing and distribution in China, as well as CSPC Ouyi Pharmaceutical Co. Ltd. for the production of traditional Chinese medicines. The product range of CSPC Pharmaceutical is diverse and offers medications for various application areas. This includes cancer therapy with products such as Anastrozole tablets and Vinorelbine injection solution. In the field of cardiovascular diseases, CSPC Pharmaceutical offers Metoprolol Succinate tablets. Additionally, the company provides products for the treatment of pain and inflammation, such as Ibuprofen suspension and generic versions of Celecoxib. Another focus of the company is the research and production of antibiotics, which are important medications in the treatment of bacterial infections. CSPC Pharmaceutical produces a wide range of antibiotics in different dosage forms, including Cefazolin Sodium injection solutions and Cefalotin Sodium injection solutions. Throughout its history, CSPC Pharmaceutical has received various awards and certifications that confirm the high quality of its products. In 2019, the company was honored as the "Best Innovative Pharmaceutical Firm" at the Asia-Pacific Biotech Industry Awards. Furthermore, CSPC Pharmaceutical has obtained the ISO 9001:2015 Quality Management System certificate, and its products are approved by the US FDA, the European Medicines Agency, and the National Medical Products Administration in China. Overall, CSPC Pharmaceutical is an important player in the Chinese pharmaceutical market, offering a wide product range and increasing the level of innovation through research and development. With its continuous growth and efforts towards quality and innovation, CSPC Pharmaceutical will continue to play a significant role in the global healthcare market.

CSPC Pharmaceutical Group SWOT Analysis

Strengths

CSPC Pharmaceutical Group Ltd has several key strengths that contribute to its success in the pharmaceutical industry. Firstly, the company has a strong portfolio of high-quality and innovative products, which have gained significant market share both domestically and internationally.

Additionally, CSPC Pharmaceutical Group Ltd has established strong relationships with healthcare providers, distributors, and key stakeholders in the industry. This allows the company to efficiently market and distribute its products and expand its customer base.

Weaknesses

Despite its successes, CSPC Pharmaceutical Group Ltd faces a few weaknesses that it should address in order to maintain its competitive edge. One weakness is its heavy reliance on a limited number of blockbuster drugs for a significant portion of its revenue. This exposes the company to potential risks if these drugs face regulatory issues or competition from generic alternatives.

Additionally, CSPC Pharmaceutical Group Ltd operates mainly in the Chinese market, which makes it vulnerable to regulatory changes and economic fluctuations specific to that region. Expanding its presence in other international markets could help mitigate this weakness.

Opportunities

There are several opportunities that CSPC Pharmaceutical Group Ltd can leverage to drive growth and further strengthen its position in the industry. One opportunity is the increasing demand for healthcare products and services in emerging markets, such as China and other Asian countries. By capitalizing on this trend, the company can expand its customer base and increase its market share.

Additionally, advancements in technology and research present opportunities for CSPC Pharmaceutical Group Ltd to develop innovative therapies and drug delivery systems. Investing in research and development can help the company stay ahead of competitors and offer cutting-edge products to meet evolving customer needs.

Threats

CSPC Pharmaceutical Group Ltd faces certain threats that could impact its business operations and growth prospects. One significant threat is increasing competition from both domestic and international pharmaceutical companies. This can result in price pressures, loss of market share, and decreased profitability.

Moreover, regulatory changes and stringent approval processes for new drugs pose a threat to CSPC Pharmaceutical Group Ltd. Delays in obtaining necessary approvals can impact product launches and revenue generation.

CSPC Pharmaceutical Group Eulerpool Fair Value

CSPC Pharmaceutical Group historical P/E ratio, EBIT multiple, and P/S ratio

CSPC Pharmaceutical Group annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

CSPC Pharmaceutical Group shares outstanding

The number of shares was CSPC Pharmaceutical Group in 2025 — This indicates how many shares 11.738 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2005
1.54 B base_Shares
Jan 1, 2006
1.54 B base_Shares
Jan 1, 2007
1.54 B base_Shares
Jan 1, 2008
1.54 B base_Shares
Jan 1, 2009
1.54 B base_Shares
Jan 1, 2010
1.54 B base_Shares
Jan 1, 2011
1.53 B base_Shares
Jan 1, 2012
4.58 B base_Shares
Jan 1, 2013
5.88 B base_Shares
Jan 1, 2014
5.97 B base_Shares
Jan 1, 2015
11.44 B base_Shares
Jan 1, 2016
11.53 B base_Shares
Jan 1, 2017
11.7 B base_Shares
Jan 1, 2018
11.98 B base_Shares
Jan 1, 2019
11.96 B base_Shares

CSPC Pharmaceutical Group Dividend History

26 years of dividend payments

YearAnnual DividendYoY ChangePayments
20250.24CNY↓ 29.4%2×
Jun 4, 20250.1CNY↑ 400.0%1/2
Oct 17, 20250.14CNY↑ 40.0%2/2
20240.34CNY↑ 36.0%4×
20230.25CNY↑ 25.0%2×
20220.2CNY↑ 17.6%2×
20210.17CNY↓ 25.0%2×
20200.23CNY↑ 25.9%2×
20190.18CNY↑ 20.0%1×
20180.15CNY↑ 25.0%1×
20170.12CNY↑ 9.1%1×
20160.11CNY↑ 10.0%1×

CSPC Pharmaceutical Group dividend history and estimates

In 2025, CSPC Pharmaceutical Group paid a dividend amounting to 0.24 CNY. Dividend means that CSPC Pharmaceutical Group distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Invalid Date
0.05 CNY
0.05 CNY
Invalid Date
0.2 CNY
0.22 CNY
Invalid Date
0.24 CNY
0.26 CNY
Invalid Date
0.24 CNY
0.26 CNY
Invalid Date
0.1 CNY
0.11 CNY
Invalid Date
0.08 CNY
0.09 CNY
Jan 1, 2015
0.1 CNY
0 CNY
Jan 1, 2016
0.11 CNY
0 CNY
Jan 1, 2017
0.12 CNY
0 CNY
Jan 1, 2018
0.15 CNY
0 CNY
Jan 1, 2019
0.18 CNY
0 CNY
Jan 1, 2020
0.23 CNY
0 CNY
Jan 1, 2021
0.17 CNY
0 CNY
Jan 1, 2022
0.2 CNY
0 CNY
Jan 1, 2023
0.25 CNY
0 CNY

CSPC Pharmaceutical Group dividend payout ratio

In 2025, CSPC Pharmaceutical Group had a payout ratio of 37.45%. The payout ratio indicates the percentage of the company's profits that CSPC Pharmaceutical Group distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2005
36.07 %
Jan 1, 2006
36.07 %
Jan 1, 2007
36.07 %
Jan 1, 2008
4.73 %
Jan 1, 2009
18.61 %
Jan 1, 2010
29.07 %
Jan 1, 2011
96.15 %
Jan 1, 2012
36.07 %
Jan 1, 2013
40.08 %
Jan 1, 2014
21.83 %
Jan 1, 2015
42.92 %
Jan 1, 2016
35.11 %
Jan 1, 2017
29.47 %
Jan 1, 2018
30.38 %
Jan 1, 2019
30.2 %
Price targets and forecasts for CSPC Pharmaceutical Group are not yet available.

CSPC Pharmaceutical Group Earnings Estimates

CSPC Pharmaceutical Group Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
5/23/20240.13CNY8.32 BCNY2024 Q1
3/20/20240.18CNY8.08 BCNY2023 Q4
8/22/20230.15CNY-CNY2023 Q2
5/23/20230.13CNY-CNY2023 Q1
3/20/20230.13CNY8.18 BCNY2022 Q4
11/16/20220.13CNY7.98 BCNY2022 Q3
8/24/20220.25CNY18.23 BCNY2022 Q2
5/25/20220.16CNY14.26 BCNY2022 Q1
3/22/20220.08CNY7.58 BCNY2021 Q4
11/18/20210.12CNY7.86 BCNY2021 Q3

EESG©

Eulerpool ESG Scorecard© for the CSPC Pharmaceutical Group stock

76/100
74
Environment
88
Social
67
Governance
E

Environment

20
Scope 1 - Direct Emissions663,224
Scope 2 - Indirect emissions from purchased energy418,037
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions1,081,261
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees48.16
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

CSPC Pharmaceutical Group shareholder structure

% Name
14.23738%
Cai (Dong Chen)
Cai (Dong Chen)
10.38363%
Massive Giant Group Ltd.
Massive Giant Group Ltd.
6.20884%
Common Success International Ltd.
Common Success International Ltd.
2.42087%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
2.33186%
UBS Asset Management (Hong Kong) Limited
UBS Asset Management (Hong Kong) Limited
2.07663%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
1.74345%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
1.42718%
China Universal Asset Management Co., Ltd.
China Universal Asset Management Co., Ltd.
1.33296%
GF Fund Management Co., Ltd.
GF Fund Management Co., Ltd.
1.13475%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
...

CSPC Pharmaceutical Group Executives and Management Board

DC

Mr. Dongchen Cai

(70)

Executive Chairman of the Board · since 1998

Compensation26.68 M CNY
CZ

Mr. Cuilong Zhang

(55)

Executive Vice Chairman of the Board, Chief Executive Officer · since 2018

Compensation13.47 M CNY
CL

Mr. Chunlei Li

(47)

Executive Director · since 2017

Compensation9.42 M CNY
HW

Mr. Huaiyu Wang

(61)

Executive Director · since 2010

Compensation5.74 M CNY
WP

Mr. Weidong Pan

(54)

Executive Director · since 2006

Compensation4.92 M CNY

CSPC Pharmaceutical Group Supply Chain

Frequently asked questions about CSPC Pharmaceutical Group

The business model of CSPC Pharmaceutical Group Ltd focuses on research, development, manufacturing, and sales of pharmaceutical products. With a comprehensive portfolio, CSPC primarily operates in the fields of antibiotics, vitamins, and cardiovascular drugs. The company leverages its strong R&D capabilities to produce innovative and high-quality medicines that address various medical needs. By maintaining a vertically integrated business model, CSPC ensures control and efficiency throughout the entire production process, from raw material procurement to final product distribution. With a commitment to technological advancement and continuous improvement, CSPC Pharmaceutical Group Ltd strives to provide safe and effective healthcare solutions to patients worldwide.

All fundamentals and in-depth analysis of CSPC Pharmaceutical Group

Our stock analysis for CSPC Pharmaceutical Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CSPC Pharmaceutical Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

CSPC Pharmaceutical Group Stock
CSPC Pharmaceutical Group Revenue→
CSPC Pharmaceutical Group Stock
CSPC Pharmaceutical Group Net Income→
CSPC Pharmaceutical Group Stock
CSPC Pharmaceutical Group P/E→
CSPC Pharmaceutical Group Stock
CSPC Pharmaceutical Group P/S→
CSPC Pharmaceutical Group Stock
CSPC Pharmaceutical Group EBIT→
CSPC Pharmaceutical Group Stock
CSPC Pharmaceutical Group Dividend→
CSPC Pharmaceutical Group Stock
CSPC Pharmaceutical Group Directors Dealings→
CSPC Pharmaceutical Group Stock
CSPC Pharmaceutical Group Stocks→
CSPC Pharmaceutical Group Stock
CSPC Pharmaceutical Group Market capitalization→
CSPC Pharmaceutical Group Stock
CSPC Pharmaceutical Group Debt→
CSPC Pharmaceutical Group Stock
CSPC Pharmaceutical Group Liabilities→
CSPC Pharmaceutical Group Stock
CSPC Pharmaceutical Group Equity→
CSPC Pharmaceutical Group Stock
CSPC Pharmaceutical Group AAQS→
CSPC Pharmaceutical Group Stock
CSPC Pharmaceutical Group Employees→
CSPC Pharmaceutical Group Stock
CSPC Pharmaceutical Group ROE→
CSPC Pharmaceutical Group Stock
CSPC Pharmaceutical Group ROA→
CSPC Pharmaceutical Group Stock
CSPC Pharmaceutical Group ROCE→